Dysthymia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<h4><strong>Market Overview:</strong></h4>

<blockquote>
<p>The 7 major dysthymia markets are expected to exhibit a CAGR of 3.7% during 2024-2034.</p>
</blockquote>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left">Report Attribute&nbsp;</div>
</th>
<th scope="col">
<div style="text-align:left">Key Statistics</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>Base Year</strong></div>
</td>
<td>
<div>2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>Forecast Years</strong></div>
</td>
<td>
<div>2024-2034</div>
</td>
</tr>
<tr>
<td>
<div><strong>Historical Years</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td><strong>Market Growth Rate 2024-2034</strong></td>
<td>3.7%</td>
</tr>
</tbody>
</table>

<p style="text-align:justify"><br />
The dysthymia market has been comprehensively analyzed in IMARC&#39;s new report titled <strong>&quot;Dysthymia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034&quot;</strong>. Dysthymia, also known as persistent depressive disorder, refers to a chronic form of depression characterized by constant feelings of sadness, low mood, and a lack of interest or pleasure in activities. Various other indications associated with the condition include sleep disturbances, changes in appetite or weight, fatigue, low self-esteem, difficulty concentrating, a sense of being overwhelmed, etc. While the symptoms of dysthymia are generally milder than those of major depressive disorder, they can significantly impact a person&#39;s daily life, relationships, and overall well-being. The diagnosis is based on the presence of certain criteria mentioned in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). These criteria include a chronic low mood lasting for at least two years in adults (or one year in children and adolescents), along with various other indications like sleep disturbances, fatigue, feelings of hopelessness, etc. The mental health professional will conduct a detailed assessment, considering the patient&#39;s medical and psychological history, family history of mental health conditions, and the impact of symptoms on daily functioning and overall well-being.</p>

<p style="text-align:center"><img alt="Dysthymia Market" src="https://www.imarcgroup.com/CKEditor/4943c109-6f80-4bc1-971c-d9badcbe9b48dysthymia-market.webp" style="height:450px; width:800px" /></p>

<p style="text-align:justify">The increasing cases of imbalances in various brain chemicals, such as serotonin, dopamine, norepinephrine, etc., that play a crucial role in regulating mood are primarily driving the dysthymia market. In addition to this, the escalating incidences of numerous associated risk factors, including genetic predisposition, traumatic early life experiences, chronic stress, comorbid conditions like anxiety and substance use disorders, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of several anti-depressant medications, such as serotonin-norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors, for managing neurotransmitter imbalances in the brain and reducing depressive indications is further bolstering the market growth. Additionally, the inflating application of light therapy, which involves exposure to bright artificial light to regulate mood and alleviate symptoms of dysthymia, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of mindfulness-based approaches, such as mindfulness-based cognitive therapy (MBCT), since they assist patients in developing greater awareness of their thoughts and emotions while reducing rumination as well as promoting self-compassion, is expected to drive the dysthymia market during the forecast period.</p>

<p style="text-align:justify">IMARC Group&#39;s new report provides an exhaustive analysis of the dysthymia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for dysthymia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysthymia market in any manner.</p>

<h4><strong>Key Highlights:</strong></h4>

<ul style="margin-left:40px">
<li style="text-align:justify">Dysthymia affects around 105 million individuals worldwide each year, or 1.5% of the population.</li>
<li style="text-align:justify">The condition is 38% more prevalent in women (1.8% of women) than in men (1.3% of men).</li>
<li>The lifetime incidence of dysthymia in community settings tends to range between 3 and 6% in the U.S.</li>
<li>In primary care settings, the rate is greater, ranging between 5 and 15%.</li>
<li style="text-align:justify">Dysthymia affects around 36% of outpatient mental health care patients.</li>
<li style="text-align:justify">According to the National Health and Nutrition Examination Survey III (NHANES III), African Americans and Mexican Americans had a higher incidence of dysthymia than Caucasians.</li>
</ul>

<p><br />
<br />
<strong>Time Period of the Study</strong></p>

<ul style="margin-left:40px">
<li>Base Year: 2023</li>
<li>Historical Period: 2018-2023</li>
<li>Market Forecast: 2024-2034
<p>&nbsp;</p>
</li>
</ul>

<p><strong>Countries Covered</strong></p>

<ul style="margin-left:40px">
<li>United States</li>
<li>Germany</li>
<li>France</li>
<li>United Kingdom</li>
<li>Italy</li>
<li>Spain</li>
<li>Japan<br />
&nbsp;</li>
</ul>

<p><strong>Analysis Covered Across Each Country</strong></p>

<ul style="margin-left:40px">
<li>Historical, current, and future epidemiology scenario</li>
<li>Historical, current, and future performance of the dysthymia market</li>
<li>Historical, current, and future performance of various therapeutic categories in the market</li>
<li>Sales of various drugs across the dysthymia market</li>
<li>Reimbursement scenario in the market</li>
<li>In-market and pipeline drugs</li>
</ul>

<h4><br />
<strong>Competitive Landscape:</strong></h4>

<p>This report also provides a detailed analysis of the current dysthymia marketed drugs and late-stage pipeline drugs.</p>

<p><strong>In-Market Drugs</strong></p>

<ul style="margin-left:40px">
<li>Drug Overview</li>
<li>Mechanism of Action</li>
<li>Regulatory Status</li>
<li>Clinical Trial Results</li>
<li>Drug Uptake and Market Performance<br />
&nbsp;</li>
</ul>

<p><strong>Late-Stage Pipeline Drugs</strong></p>

<ul style="margin-left:40px">
<li>Drug Overview</li>
<li>Mechanism of Action</li>
<li>Regulatory Status</li>
<li>Clinical Trial Results</li>
<li>Drug Uptake and Market Performance</li>
</ul>

<h4><br />
<strong>Key Questions Answered in this Report:</strong></h4>

<p><strong>Market Insights</strong></p>

<ul style="margin-left:40px">
<li>How has the dysthymia market performed so far and how will it perform in the coming years?</li>
<li>What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?</li>
<li>What was the country-wise size of the dysthymia market across the seven major markets in 2023 and what will it look like in 2034?</li>
<li>What is the growth rate of the dysthymia market across the seven major markets and what will be the expected growth over the next ten years?</li>
<li>What are the key unmet needs in the market?<br />
&nbsp;</li>
</ul>

<p><strong>Epidemiology Insights</strong></p>

<ul style="margin-left:40px">
<li>What is the number of prevalent cases (2018-2034) of dysthymia across the seven major markets?</li>
<li>What is the number of prevalent cases (2018-2034) of dysthymia by age across the seven major markets?</li>
<li>What is the number of prevalent cases (2018-2034) of dysthymia by gender across the seven major markets?</li>
<li>How many patients are diagnosed (2018-2034) with dysthymia across the seven major markets?</li>
<li>What is the size of the dysthymia patient pool (2018-2023) across the seven major markets?</li>
<li>What would be the forecasted patient pool (2024-2034) across the seven major markets?</li>
<li>What are the key factors driving the epidemiological trend of dysthymia?</li>
<li>What will be the growth rate of patients across the seven major markets?<br />
&nbsp;</li>
</ul>

<p><strong>Dysthymia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies</strong></p>

<ul style="margin-left:40px">
<li>What are the current marketed drugs and what are their market performance?</li>
<li>What are the key pipeline drugs and how are they expected to perform in the coming years?</li>
<li>How safe are the current marketed drugs and what are their efficacies?</li>
<li>How safe are the late-stage pipeline drugs and what are their efficacies?</li>
<li>What are the current treatment guidelines for dysthymia drugs across the seven major markets?</li>
<li>Who are the key companies in the market and what are their market shares?</li>
<li>What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysthymia market?</li>
<li>What are the key regulatory events related to the dysthymia market?</li>
<li>What is the structure of clinical trial landscape by status related to the dysthymia market?</li>
<li>What is the structure of clinical trial landscape by phase related to the dysthymia market?</li>
<li>What is the structure of clinical trial landscape by route of administration related to the dysthymia market?&nbsp;</li>
</ul>

<h4><strong>市场概览：</strong></h4>

<blockquote>
<p>预计在2024-2034年间，7个主要抑郁症市场将呈现出3.7%的复合年增长率。</p>
</blockquote>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left">报告属性</div>
</th>
<th scope="col">
<div style="text-align:left">关键统计数据</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>基准年</strong></div>
</td>
<td>
<div>2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>预测年份</strong></div>
</td>
<td>
<div>2024-2034</div>
</td>
</tr>
<tr>
<td>
<div><strong>历史年份</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td><strong>2024-2034年市场增长率</strong></td>
<td>3.7%</td>
</tr>
</tbody>
</table>

<p style="text-align:justify"><br />
IMARC集团的新报告《抑郁症市场：流行病学、行业趋势、份额、规模、增长、机遇和预测2024-2034》对抑郁症市场进行了全面分析。抑郁症，亦称持续性抑郁症，是一种以持续的悲伤、低落情绪以及对活动缺乏兴趣或愉悦为特征的慢性抑郁症。与该病症相关的其他各种症状包括睡眠障碍、食欲或体重变化、疲劳、自尊心低下、注意力难以集中、感到不堪重负等。虽然抑郁症的症状通常比重度抑郁症的症状轻微，但它们可能会严重影响一个人的日常生活、人际关系和整体福祉。诊断基于《精神疾病诊断与统计手册》（DSM-5）中提到的某些标准。这些标准包括成年人（或儿童和青少年）至少持续两年的慢性低落情绪，以及各种其他症状，如睡眠障碍、疲劳、感到绝望等。心理健康专业人员将进行详细评估，考虑患者的医疗和心理病史、心理健康状况的家庭史以及症状对日常生活和整体福祉的影响。</p>

<p style="text-align:center"><img alt="抑郁症市场" src="https://www.imarcgroup.com/CKEditor/4943c109-6f80-4bc1-971c-d9badcbe9b48dysthymia-market.webp" style="height:450px; width:800px" /></p>

<p style="text-align:justify">脑化学物质（如血清素、多巴胺、去甲肾上腺素等）失衡的病例不断增加，这些化学物质在调节情绪中起着至关重要的作用，这主要是推动抑郁症市场增长的因素。除此之外，与遗传易感性、创伤性早年经历、慢性压力、共病状况（如焦虑和物质使用障碍）等众多相关风险因素相关病例的增加，也为市场的发展提供了积极的展望。此外，抗抑郁药物（如血清素-去甲肾上腺素再摄取抑制剂和选择性血清素再摄取抑制剂）的广泛应用，这些药物用于管理大脑中的神经递质失衡并减少抑郁症状，进一步推动了市场增长。此外，光疗的广泛应用，即暴露于明亮的模拟光线以调节情绪并缓解抑郁症症状，也是推动市场增长的重要因素。此外，基于正念的方法（如正念认知疗法（MBCT））的兴起，因为它们有助于患者增强对自身思想和情绪的认识，同时减少沉思并促进自我同情，预计将在预测期内推动抑郁症市场。</p>

<p style="text-align:justify">IMARC集团的新报告对美国的抑郁症市场、欧盟4国（德国、西班牙、意大利和法国）、英国和日本的抑郁症市场进行了全面分析。这包括治疗实践、上市和管道药物、个别疗法的市场份额、七个主要市场的市场表现、关键公司的药物市场表现等。该报告还提供了七个主要市场的当前和未来患者池。根据该报告，美国拥有最大的抑郁症患者群，也是其治疗市场最大的市场。此外，该报告还提供了当前的治疗实践/算法、市场驱动因素、挑战、机遇、补偿情景、未满足的医疗需求等。该报告对制造商、投资者、商业战略家、研究人员、顾问以及所有以任何方式参与或计划进入抑郁症市场的人士都是必读之作。</p>

<h4><strong>关键亮点：</strong></h4>

<ul style="margin-left:40px">
<li style="text-align:justify">抑郁症每年影响全球约1.05亿人，约占人口的1.5%。</li>
<li style="text-align:justify">该病症在女性（女性占1.8%）中比在男性（男性占1.3%）中更为普遍，高出38%。</li>
<li>美国社区环境中抑郁症的终身发病率通常在3%到6%之间。</li>
<li>在初级保健环境中，该比率更高，介于5%到15%之间。</li>
<li style="text-align:justify">抑郁症影响约36%的门诊心理健康护理患者。</li>
<li style="text-align:justify">根据国家健康与营养调查III（NHANES III），非裔美国人和墨西哥裔美国人的抑郁症发病率高于白人。</li>
</ul>

<p><br />
<br />
<strong>研究时间范围</strong></p>

<ul style="margin-left:40px">
<li>基准年：2023</li>
<li>历史时期：2018-2023</li>
<li>市场预测：2024-2034</li>
</ul>

<p><strong>涵盖的国家</strong></p>

<ul style="margin-left:40px">
<li>美国</li>
<li>德国</li>
<li>法国</li>
<li>英国</li>
<li>意大利</li>
<li>西班牙</li>
<li>日本</li>
</ul>

<p><strong>每个国家的分析覆盖范围</strong></p>

<ul style="margin-left:40px">
<li>历史、当前和未来的流行病学情景</li>
<li>历史、当前和未来的抑郁症市场表现</li>
<li>市场各种治疗类别的历史、当前和未来表现</li>
<li>抑郁症市场各种药物的销售额</li>
<li>市场补偿情景</li>
<li>上市和管道药物</li>
</ul>

<h4><br />
<strong>竞争格局：</strong></h4>

<p>本报告还提供了当前抑郁症上市药物和后期管道药物的详细分析。</p>

<p><strong>上市药物</strong></p>

<ul style="margin-left:40px">
<li>药物概述</li>
<li>作用机制</li>
<li>监管状态</li>
<li>临床试验结果</li>
<li>药物普及度和市场表现</li>
</ul>

<p><strong>后期管道药物</strong></p>

<ul style="margin-left:40px">
<li>药物概述</li>
<li>作用机制</li>
<li>监管状态</li>
<li>临床试验结果</li>
<li>药物普及度和市场表现</li>
</ul>

<h4><br />
<strong>本报告回答的关键问题：</strong></h4>

<p><strong>市场洞察</strong></p>

<ul style="margin-left:40px">
<li>抑郁症市场迄今为止的表现如何？未来几年将如何表现？</li>
<li>2023年各种治疗领域的市场份额是多少？预计到2034年将如何表现？</li>
<li>2023年七个主要市场的抑郁症市场规模是多少？2034年将如何？</li>
<li>七个主要市场的抑郁症市场增长率是多少？预计未来十年将增长多少？</li>
<li>市场的主要未满足需求是什么？</li>
</ul>

<p><strong>流行病学洞察</strong></p>

<ul style="margin-left:40px">
<li>七个主要市场抑郁症的现患病例（2018-2034）数量是多少？</li>
<li>七个主要市场抑郁症的现患病例（2018-2034）按年龄分布如何？</li>
<li>七个主要市场抑郁症的现患病例（2018-2034）按性别分布如何？</li>
<li>七个主要市场有多少患者被诊断为抑郁症（2018-2034）？</li>
<li>七个主要市场的抑郁症患者池（2018-2023）规模是多少？</li>
<li>七个主要市场的预测患者池（2024-2034）将是多少？</li>
<li>驱动抑郁症流行病学趋势的关键因素是什么？</li>
<li>七个主要市场的患者增长率将是多少？</li>
</ul>

<p><strong>抑郁症：当前治疗情景、上市药物和新兴疗法</strong></p>

<ul style="margin-left:40px">
<li>当前上市药物有哪些？它们的销售表现如何？</li>
<li>关键管道药物有哪些？预计在未来几年将如何表现？</li>
<li>当前上市药物的安全性如何？它们的疗效如何？</li>
<li>后期管道药物的安全性如何？它们的疗效如何？</li>
<li>七个主要市场的抑郁症药物当前的治疗指南是什么？</li>
<li>市场中的关键公司有哪些？它们的市场份额是多少？</li>
<li>与抑郁症市场相关的关键并购、许可活动、合作等有哪些？</li>
<li>与抑郁症市场相关的关键监管事件有哪些？</li>
<li>与抑郁症市场相关的临床试验景观按状态如何？</li>
<li>与抑郁症市场相关的临床试验景观按阶段如何？</li>
<li>与抑郁症市场相关的临床试验景观按给药途径如何？</li>
</ul>